[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 26 days · First seen · Last updated

Natera, Inc. business and market developments

Overview

Natera, Inc. has experienced growth in both its market valuation and strategic clinical applications. In September 2026, CEO Steven Chapman reported strong second-quarter performance, including nearly 40% year-over-year sales growth and record volumes for Signatera tests. During this period, Chapman executed a scheduled sale of approximately $545,000 in stock under a Rule 10b5-1 plan.

By October 2026, the company’s market outlook improved as TD Cowen raised its price target from $340.00 to $480.00. Natera also entered a strategic collaboration with TransCode Therapeutics to utilize Signatera in a Phase 2a study for colorectal cancer. This development follows the US FDA granting Breakthrough Device designation to Natera’s multi-cancer early detection blood test. Institutional investors continue to hold a dominant position in the company, owning 99.90% of its stock.

Entities

Natera, Inc. · BlackRock Inc. · TransCode Therapeutics · Mike Brophy · Steven Chapman

Timeline

  1. [BUSINESS] 2 sources
    Natera, Inc. sees price target hike and new strategic partnership

    TD Cowen raised its price target for Natera, Inc. to $480.00 amid new strategic collaborations and significant institutional investment in the medical diagnostics firm.

  2. [BUSINESS] 2 sources
    Natera CEO Steven Chapman sells $545,000 in stock amid strong growth reports

    Natera CEO Steven Chapman sold $545,000 in stock via a pre-scheduled plan, while company leadership reported record Signatera test volumes and strong growth at a Morgan Stanley healthcare conference.

Sources

ad-hoc-news.de · seekingalpha.com · stocknews.com · theascent.com